Beam generated $175 million in premiums last year, and the deal targets Principal's specialty benefits 5-9% growth range ...
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency ...
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for ...
Beam Therapeutics Inc. Annual stock financials by MarketWatch. View the latest BEAM financial statements, income statements and financial ratios.
Shares of Prime Medicine rose after the company said an arbitration tribunal ruled that PM647, a treatment it is developing for alpha-1 antitrypsin deficiency, is within Prime's field under its 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results